{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:23:06Z","timestamp":1790364186164,"version":"4.1.0"},"reference-count":27,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: The Human Papillomavirus (HPV) vaccine has been globally implemented to prevent HPV-associated diseases. Since its introduction in China in 2017, this vaccine has substantially reduced the burden of HPV-related health conditions. As more people get vaccinated these days, ongoing safety monitoring and evaluation have become critical. This helps to safeguard public trust in immunization programs and ensures the sustainability of immunization programs. Methods: Suspected adverse events following immunization (AEFIs) associated with HPV vaccination from 2017 to 2024 were extracted from the Chinese National Immunization Information System (CNIIS). Data on the number of HPV vaccine doses given came from the Immunization Planning Information Management System of Anhui Province. Descriptive statistical methods examined the distribution characteristics of AEFIs, and chi-square tests assessed differences in incidence rates. Results: From 2017 to 2024, the vaccine safety surveillance system in Anhui Province monitored a total of 1149 reports of AEFIs associated with the HPV vaccine. The reported overall rate of AEFIs was 16.32 per 100,000 doses. Specifically, the rates of common adverse reactions were 15.15 per 100,000 doses, while the rates for rare adverse reactions were 0.85 per 100,000. Among the common adverse reactions, the incidence rates of injection-site redness and swelling (diameter &gt;5.0 cm), induration (diameter &gt;5.0 cm), and fever (axillary temperature \u226538.6 \u00b0C) were 0.60, 0.33, and 1.34 per 100,000 doses, respectively. For rare adverse reactions, the reported incidence rates of allergic rash, allergic urticaria, and aseptic abscess were 0.50, 0.09, and 0.03 per 100,000 doses, respectively. Most AEFIs occurred within 24 h post-vaccination. Conclusions: The overall reported incidence of AEFIs following HPV vaccination in Anhui Province from 2017 to 2024 was low, with serious rare adverse reaction occurring infrequently. These findings suggest that the HPV vaccine has a favorable safety profile.<\/jats:p>","DOI":"10.3390\/vaccines13080846","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:02:09Z","timestamp":1754910129000},"page":"846","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Post-Marketing Safety Surveillance of HPV Vaccines in Anhui Province, China, 2017\u20132024"],"prefix":"10.3390","volume":"13","author":[{"given":"Fanya","family":"Meng","sequence":"first","affiliation":[{"name":"Anhui Provincial Center for Disease Control and Prevention, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Hu","sequence":"additional","affiliation":[{"name":"School of Public Health, Bengbu Medical University, Bengbu 233030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbing","family":"Wang","sequence":"additional","affiliation":[{"name":"Anhui Provincial Center for Disease Control and Prevention, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianwei","family":"Luo","sequence":"additional","affiliation":[{"name":"Anhui Provincial Center for Disease Control and Prevention, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Xu","sequence":"additional","affiliation":[{"name":"Fuyan Center for Disease Control and Prevention, Fuyang 236000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangshun","family":"Wan","sequence":"additional","affiliation":[{"name":"Anqin Center for Disease Control and Prevention, Anqing 246003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Xue","sequence":"additional","affiliation":[{"name":"Anhui Provincial Center for Disease Control and Prevention, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Su","sequence":"additional","affiliation":[{"name":"Anhui Provincial Center for Disease Control and Prevention, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Sun","sequence":"additional","affiliation":[{"name":"Anhui Provincial Center for Disease Control and Prevention, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabing","family":"Wu","sequence":"additional","affiliation":[{"name":"Anhui Provincial Center for Disease Control and Prevention, Hefei 230601, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of Incidence and Mortality of Cervical Cancer in 2018: A Worldwide Analysis","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_2","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2024). Global Cancer Observatory: Cancer Today, International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/23-cervix-uteri-fact-sheet.pdf."},{"key":"ref_4","first-page":"2586","article-title":"Research status in application and safety research of preventive human papillomavirus vaccine","volume":"40","author":"Luo","year":"2024","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"ref_5","first-page":"249","article-title":"Development and application of prophylactic human papilloma virus vaccines in China","volume":"27","author":"Chen","year":"2023","journal-title":"Chin. J. Dis. Control. Prev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Li, M., Zhao, C., Zhao, Y., Li, J., and Wei, L. (2023). Immunogenicity, Efficacy, and Safety of Human Papillomavirus Vaccine: Data from China. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1112750"},{"key":"ref_7","unstructured":"Ministry of Health of China, State Food and Drug Administration of, China Notice on the Issuance of the National Program for Monitoring Adverse Events Following Immunization (AEFI), Available online: https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/qita\/20100603120001618.html."},{"key":"ref_8","unstructured":"Anhui Provincial Bureau of Statistics Anhui Provincial Population Census Yearbook 2020, Available online: https:\/\/tjj.ah.gov.cn\/ssah\/qwfbjd\/tjnj\/ahrkpc2020ebook\/index.htm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV Vaccination and the Risk of Invasive Cervical Cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(20)30157-4","article-title":"Mortality Impact of Achieving WHO Cervical Cancer Elimination Targets: A Comparative Modelling Analysis in 78 Low-Income and Lower-Middle-Income Countries","volume":"395","author":"Canfell","year":"2020","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.46234\/ccdcw2024.080","article-title":"Estimated Human Papillomavirus Vaccine Coverage Among Females 9-45 Years of Age\u2014China, 2017-2022","volume":"6","author":"Chen","year":"2024","journal-title":"China CDC Wkly."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.15585\/mmwr.mm7243a1","article-title":"Routine Vaccination Coverage\u2014Worldwide, 2022","volume":"72","author":"Kaur","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"You, D., Han, L., Li, L., Hu, J., Zimet, G.D., Alias, H., Danaee, M., Cai, L., Zeng, F., and Wong, L.P. (2020). Human Papillomavirus (HPV) Vaccine Uptake and the Willingness to Receive the HPV Vaccination among Female College Students in China: A Multicenter Study. Vaccines, 8.","DOI":"10.3390\/vaccines8010031"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.vaccine.2020.11.029","article-title":"A Nationwide Post-Marketing Survey of Knowledge, Attitude and Practice toward Human Papillomavirus Vaccine in General Population: Implications for Vaccine Roll-out in Mainland China","volume":"39","author":"Hu","year":"2021","journal-title":"Vaccine"},{"key":"ref_15","unstructured":"Zhang, J.X. (2024). HPV Vaccine Free Vaccination Policy Has Covered 40% of Eligible Girls. Sci. Technol. Dly., 002."},{"key":"ref_16","first-page":"451","article-title":"Surveillance for adverse events following immunization with human papillomavirus vaccines in China, 2017\u20132020","volume":"29","author":"Zhang","year":"2023","journal-title":"Chin. J. Vaccines Immun."},{"key":"ref_17","first-page":"707","article-title":"Analysis on surveillance of adverse events following immunization of human papillomavirus vaccine in Guangdong, 2018\u20132020","volume":"48","author":"Zhou","year":"2022","journal-title":"South China J. Prev. Med."},{"key":"ref_18","first-page":"1110","article-title":"Surveillance analysis of adverse events following immunization with the bivalent human papillomavirus vaccine and recombinant human papillomavirus 9-valent vaccine in Hebei province from 2018 to 2022","volume":"40","author":"Wang","year":"2024","journal-title":"Chin. J. Public Health"},{"key":"ref_19","first-page":"748","article-title":"Surveillance of adverse events following immunization with human papilloma virus vaccine in Jiangxi, 2017\u20132022","volume":"51","author":"Zheng","year":"2024","journal-title":"Mod. Prev. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e20191791","DOI":"10.1542\/peds.2019-1791","article-title":"Safety of the 9-Valent Human Papillomavirus Vaccine","volume":"144","author":"Shimabukuro","year":"2019","journal-title":"Pediatrics"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Di Lorenzo, A., Berardi, P., Martinelli, A., Bianchi, F.P., Tafuri, S., and Stefanizzi, P. (2022). Real-Life Safety Profile of the 9-Valent HPV Vaccine Based on Data from the Puglia Region of Southern Italy. Vaccines, 10.","DOI":"10.3390\/vaccines10030419"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.1016\/j.vaccine.2020.06.039","article-title":"Adverse Events Following HPV Vaccination: 11 Years of Surveillance in Australia","volume":"38","author":"Phillips","year":"2020","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Egoavil, C.M., Tuells, J., Carreras, J.J., Montagud, E., Pastor-Villalba, E., Caballero, P., and Nolasco, A. (2020). Trends of Adverse Events Following Immunization (AEFI) Reports of Human Papillomavirus Vaccine in the Valencian Community-Spain (2008\u20132018). Vaccines, 8.","DOI":"10.3390\/vaccines8010117"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Dey, A., Wang, H., Quinn, H., Pillsbury, A., Hickie, M., Deng, L., Wood, N., Beard, F., and Macartney, K. (2022). Surveillance of Adverse Events Following Immunisation in Australia Annual Report, 2020. Commun. Dis. Intell. (2018), 46.","DOI":"10.33321\/cdi.2022.46.47"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2315653","DOI":"10.1080\/21645515.2024.2315653","article-title":"Real-World Data of China: Analysis of HPV Vaccine Coverage and Post-Vaccination Adverse Reaction Monitoring in Western Chinese Provinces from 2018 to 2021","volume":"20","author":"An","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_26","first-page":"313","article-title":"Monitoring results of adverse events following immunization of human papillomavirus vaccine in Zhengzhou city from 2019 to 2022","volume":"35","author":"Fan","year":"2024","journal-title":"Mod. Dis. Control Prev."},{"key":"ref_27","unstructured":"Lingnan Cervical Cancer Prevention and Control Alliance of the Third Affiliated Hospital of Sun Yat-sen University, and Professional Committee on Cervical Cancer Prevention and Control of Guangdong Preventive Medicine Association (2023). Chinese expert consensuson the safety of human papillomavirus vaccination. J. Chin. Physician, 25, 1644\u20131660."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/8\/846\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:27:17Z","timestamp":1760034437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/8\/846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["vaccines13080846"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13080846","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]}}}